

| Catalog No. | MB011014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Species reactivity | Mouse | ||||||||
| Applications | ELISA, IHC, WB | ||||||||
| Host species | Rabbit | ||||||||
| Clonality | Polyclonal | ||||||||
| Isotype | IgG | ||||||||
| Immunogen | E. coli - derived recombinant Mouse CD22 (Val146-Glu343). | ||||||||
| Target | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14 | ||||||||
| Endotoxin level | Please contact with the lab for this information. | ||||||||
| Purity | >90% as determined by SDS-PAGE. | ||||||||
| Purification | Purified by antigen affinity column. | ||||||||
| Accession | P35329 | ||||||||
| Form | Liquid | ||||||||
| Storage buffer | 0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
||||||||
| Product Usage Information |
| ||||||||
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||||||
| Background | B-cell receptor CD22 is a ~97 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Kelm, S. et al. (1994) Current biology : CB 4, 965-72. PMID: 7533044 2. Nitschke, L. et al. (1997) Current biology : CB 7, 133-43. PMID: 9016707 | ||||||||
| Note | For research use only. |



Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский